Sjogren’s Syndrome | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2018
Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands that may occur alone (primary SS) or with a comorbid autoimmune condition (secondary SS). At present, symptomatic therapies to treat dry eyes, dry mouth, or specific extraglandular manifestations are the cornerstone of disease management. Systemic manifestations are most often treated with hydroxychloroquine or, in severe cases, with systemic immunomodulators (e.g., azathioprine, methotrexate). Emerging therapies with disease-modifying potential are now in development for SS, targeting key pathways believed to drive pathological processes in the disease. These putative disease-modifying therapies have the potential to transform the management of SS, although SS has historically proven to be a challenging indication in which to succeed.
QUESTIONS ANSWERED
- How large is the SS population and how will its size change over time?
- How is SSmanaged? Which are the most important drugs and what drives their use?
- Which unfulfilled clinical needs are most pressing?
- What pipeline products are most promising, and what sales might they garner in the SS market? What therapies of note are progressing in earlier phases?
- What are the drivers and constraints in the SS market, and how will the market evolve through 2027?
PRODUCT DESCRIPTION
Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
